Its cheap valuation, strong growth prospects, and massive dividend make it ripe for outsize investment returns.
The approval for the vaccine, Abrysvo, in adults aged 18 to 59 was based on the results from a late stage trial in which two doses of the vaccine were teste ...
Claims are spreading online about what the detection of the polio virus in London sewage means. Health officials believe the ...
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine ...
Despite that cash windfall, Pfizer has "dramatically underperformed its peers and the market since 2019," according to ...
Platelets are cells that help your blood clot, and it was so unusual to see blood clots combined with low platelet levels, ...
This is an audio transcript of the Behind the Money podcast episode: ‘An activist tried to take on Pfizer. Then things got ...
Pfizer (PFE) announced that the U.S. FDA has approved Abrysvo, the company’s bivalent RSV prefusion F vaccine, for the prevention of ...
Tuesday's approval makes Abrysvo the first RSV vaccine indicated for adults younger than 50, the biopharmaceutical company said. Last year, it was approved for use by those 60 years and older, as well ...
The UK Government has recommended offering a COVID-19 booster vaccination in autumn, 2024, to individuals at high risk of ...
Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the ...
The U.S. FDA has approved Pfizer's respiratory syncytial virus vaccine Abrysvo for individuals 18 to 59 years old that are at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback